PURPOSE: Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs). The proportion of patients who are hospitalized for irAEs and their spectrum, management, and outcomes are not well described. METHODS: We report the proportion of hospitalized patients in an academic center who were treated with ICIs from May to December 2017. Patient characteristics, toxicities, management, and outcomes for confirmed irAE admissions are reported. Associations between patient features and irAE hospitalizations are examined. RESULTS: Twenty-three percent (n = 100) of 443 patients who were admitted to an academic oncology center over 6 months had ever received ICIs. Of these patients, 41% were admitted for suspected irAEs and 23% were confirmed irAEs. IrAEs accounted for 5% of all oncology hospitalizations (n = 23). Ninety-one percent of patients with confirmed irAEs prompted a medicine subspecialist consultation, most commonly gastroenterology (22%). Fifteen patients (65%) had their irAEs improve/resolve, seven (30%) had worsening irAEs, and three (13%) died of their irAEs. The majority of patients (n = 20; 87%) discontinued ICIs after discharge. Among ICI-treated patients who required admission, an increased likelihood of irAE-related hospitalization was associated with patient age older than 65 years (odds ratio, 5.4; 95% CI, 1.6 to 17.8) and receipt of combination immunotherapy (OR, 6.8; 95% CI, 2.0 to 23.2). CONCLUSION: A notable proportion of ICI-treated patients are hospitalized for irAEs, and these patients have a high demand for multidisciplinary management. Older age and combination ICI treatment were associated with an increased risk of irAE-related hospitalization. Whereas these data are from an academic center and include patients in clinical trials, with expanding use of ICIs, these data have important implications for inpatient service planning and risk stratification.
PURPOSE: Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs). The proportion of patients who are hospitalized for irAEs and their spectrum, management, and outcomes are not well described. METHODS: We report the proportion of hospitalized patients in an academic center who were treated with ICIs from May to December 2017. Patient characteristics, toxicities, management, and outcomes for confirmed irAE admissions are reported. Associations between patient features and irAE hospitalizations are examined. RESULTS: Twenty-three percent (n = 100) of 443 patients who were admitted to an academic oncology center over 6 months had ever received ICIs. Of these patients, 41% were admitted for suspected irAEs and 23% were confirmed irAEs. IrAEs accounted for 5% of all oncology hospitalizations (n = 23). Ninety-one percent of patients with confirmed irAEs prompted a medicine subspecialist consultation, most commonly gastroenterology (22%). Fifteen patients (65%) had their irAEs improve/resolve, seven (30%) had worsening irAEs, and three (13%) died of their irAEs. The majority of patients (n = 20; 87%) discontinued ICIs after discharge. Among ICI-treated patients who required admission, an increased likelihood of irAE-related hospitalization was associated with patient age older than 65 years (odds ratio, 5.4; 95% CI, 1.6 to 17.8) and receipt of combination immunotherapy (OR, 6.8; 95% CI, 2.0 to 23.2). CONCLUSION: A notable proportion of ICI-treated patients are hospitalized for irAEs, and these patients have a high demand for multidisciplinary management. Older age and combination ICI treatment were associated with an increased risk of irAE-related hospitalization. Whereas these data are from an academic center and include patients in clinical trials, with expanding use of ICIs, these data have important implications for inpatient service planning and risk stratification.
Authors: Claire F Friedman; Varina Clark; Andrew V Raikhel; Tim Barz; Alexander N Shoushtari; Parisa Momtaz; Margaret K Callahan; Jedd D Wolchok; Paul B Chapman; Matthew D Hellmann; Michael A Postow Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Guillermo De Velasco; Youjin Je; Dominick Bossé; Mark M Awad; Patrick A Ott; Raphael B Moreira; Fabio Schutz; Joaquim Bellmunt; Guru P Sonpavde; F Stephen Hodi; Toni K Choueiri Journal: Cancer Immunol Res Date: 2017-02-28 Impact factor: 11.151
Authors: Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Daniel Y Wang; Joe-Elie Salem; Justine V Cohen; Sunandana Chandra; Christian Menzer; Fei Ye; Shilin Zhao; Satya Das; Kathryn E Beckermann; Lisa Ha; W Kimryn Rathmell; Kristin K Ancell; Justin M Balko; Caitlin Bowman; Elizabeth J Davis; David D Chism; Leora Horn; Georgina V Long; Matteo S Carlino; Benedicte Lebrun-Vignes; Zeynep Eroglu; Jessica C Hassel; Alexander M Menzies; Jeffrey A Sosman; Ryan J Sullivan; Javid J Moslehi; Douglas B Johnson Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777
Authors: Laura C Kennedy; Kit Man Wong; Nikhil V Kamat; Ali Raza Khaki; Shailender Bhatia; John A Thompson; Petros Grivas Journal: Target Oncol Date: 2020-08 Impact factor: 4.493
Authors: Kai-Li Liang; Sean Tackett; Samantha Myers; Julie R Brahmer; Ilene S Browner; David S Ettinger; Patrick M Forde; Russell K Hales; Christine L Hann; Vincent K Lam; Kristen A Marrone; Tricia Patel; Valerie Peterson; Sarah Sagorsky; Michelle Turner; Khinh R Voong; Jarushka Naidoo; Josephine L Feliciano Journal: Curr Oncol Date: 2022-06-17 Impact factor: 3.109
Authors: Gabriel E Molina; Leyre Zubiri; Justine V Cohen; Sienna M Durbin; Laura Petrillo; Ian M Allen; Yonina R Murciano-Goroff; Michael Dougan; Molly F Thomas; Alexander T Faje; Michelle Rengarajan; Amanda C Guidon; Steven T Chen; Daniel Okin; Benjamin D Medoff; Mazen Nasrallah; Minna J Kohler; Sara R Schoenfeld; Rebecca S Karp Leaf; Meghan E Sise; Tomas G Neilan; Daniel A Zlotoff; Jocelyn R Farmer; Meghan J Mooradian; Aditya Bardia; Minh Mai; Ryan J Sullivan; Yevgeniy R Semenov; Alexandra Chloé Villani; Kerry L Reynolds Journal: Oncologist Date: 2021-03-31
Authors: Saby George; Elizabeth J Bell; Ying Zheng; Ruth Kim; John White; Geeta Devgan; Jodi Smith; Lincy S Lal; Nicole M Engel-Nitz; Frank X Liu Journal: Oncologist Date: 2021-05-29
Authors: Erin E Kent; Eliza M Park; William A Wood; Ashley Leak Bryant; Michelle A Mollica Journal: J Clin Oncol Date: 2021-05-27 Impact factor: 50.717
Authors: Anish B Parikh; Xiaobo Zhong; George Mellgard; Qian Qin; Vaibhav G Patel; Bo Wang; Parissa Alerasool; Philip Garcia; Amanda Leiter; Emily J Gallagher; Steven Clinton; Amir Mortazavi; Paul Monk; Edmund Folefac; Ming Yin; Yuanquan Yang; Matthew Galsky; William K Oh; Che-Kai Tsao Journal: Am J Clin Oncol Date: 2021-03-01 Impact factor: 2.787
Authors: Nežka Hribernik; Daniel T Huff; Andrej Studen; Katarina Zevnik; Žan Klaneček; Hamid Emamekhoo; Katja Škalic; Robert Jeraj; Martina Reberšek Journal: Eur J Nucl Med Mol Imaging Date: 2021-12-27 Impact factor: 10.057